Table 1.

Characteristics of included studies.

Study	Year	Country	Time frame	Sample size	Age (median, year)	Histology	FIGO Stage	Follow-up duration (median)	Treatment strategy	Cut-off value
Jonska-Gmyrek et al	2018	Poland	2003–2008	94	53	ADC	IA–IVB	66 mons	Mixed	1.6
Nuchpramool et al	2018	Thailand	2001–2016	460	47	Mixed	IA2–IB1	57 mons	Surgery ± AT	1.8
Ida et al	2018	Japan	2004–2015	79	52.4#	Mixed	NR	15 mons	Mixed	2.8
Holub et al	2018	Spain	2009–2016	151	51	Mixed	IA–IVB	44 mons	Mixed	3.8
He et al	2018	China	2007–2009	229	44	Mixed	I–IV	83 mons	Mixed	1.6
Koulis et al	2017	Canada	1998–2012	257	50	Mixed	IB–IVA	41 mons	CCRT or RT	5
Cho et al.*	2016	Korea	1986–2012	2456	56	Mixed	IA–IVA	65 mons	CCRT or RT	2.5
Wang et al.*	2016	China	2009–2010	60	53	SCC	II–III	58 mons	CCRT	2
Onal et al.*	2016	Turkey	2006–2014	235	57	Mixed	IB2–IVA	32 mons	CCRT	3.03
Haraga et al.*	2016	Japan	2007–2013	36	61.5#	Mixed	IB1–IVA	30 mons	RT	2.85
Chen et al.*	2016	China	2006–2009	407	44	NR	IB1–IIA	NR	Surgery ± AT	2.42
Mizunuma et al.*	2015	Japan	2005–2013	56	65.1	SCC	IB1–IV	14 mons#	CCRT or RT	2.5
Zhang et al.*	2014	China	2005–2008	460	44	Mixed	I–II	69 mons	Surgery ± AT	2.213
Lee et al.*	2012	Korea	1996–2007	1061	50	Mixed	IB1–IVA	53 mons	Mixed	1.9

NR not reported,  ± AT with/without adjuvant therapy, CCRT cisplatin-based concurrent chemoradiotherapy, RT radiotherapy, ADC adenocarcinoma of cervix, SCC squamous carcinoma of cervix, FIGO International Federation of Gynecology and Obstetrics.

^#Mean age of the sample.

^#Mean follow up duration of the sample.

*Included in previous meta-analysis.